Premium
Bevacizumab in association with de Gramont 5‐fluorouracil/folinic acid in patients with oxaliplatin‐, irinotecan‐, and cetuximab‐refractory colorectal cancer
Author(s) -
Vincenzi Bruno,
Santini Daniele,
Russo Antonio,
Spoto Chiara,
Venditti Olga,
Gasparro Simona,
Rizzo Sergio,
Zobel Bruno Beomonte,
Caricato Marco,
Valeri Sergio,
Coppola Roberto,
Tonini Giuseppe
Publication year - 2009
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24540
Subject(s) - medicine , folinic acid , irinotecan , cetuximab , oxaliplatin , bevacizumab , colorectal cancer , fluorouracil , oncology , refractory (planetary science) , chemotherapy , cancer , physics , astrobiology
BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab + 5‐fluorouracil(5–FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options. METHODS: The authors included 48 heavily pretreated patients (colon:rectum, 33:15; men:women, 23:25; median age, 63 years; range, 27‐79 years) whose disease had progressed during or within an oxaliplatin‐based first‐line chemotherapy, an irinotecan‐based second‐line regimen, and a third‐line treatment with cetuximab plus weekly irinotecan. Bevacizumab was given at a dose of 5 mg/kg. 5‐FU/folinic acid was administered according to the de Gramont schedule. RESULTS: The response rate was 6.25%, and 30.4% of patients demonstrated stable disease as the best response. The median time to disease progression was 3.5 months (95% confidence interval [95% CI], 2.3‐6.9 months), and the median survival time was 7.7 months (95% CI, 3.9‐11.9 months). The most common grade 3 to 4 side toxicities (graded according to the National Cancer Institute Common Toxicity Criteria [version 2.0]) were: diarrhea (20.8%), fatigue (14.5%), and stomatitis (12.5%). Grade 3 to 4 hemorrhage occurred in 8 patients (16.6%), including 4 cases of bleeding in the gastrointestinal tract. Other relatively common adverse events such as hypertension, thrombosis, and bowel perforation were reported in 50%, 18.7%, and 4.16%, of patients respectively. CONCLUSIONS: The data from the current study suggest a modest but significant clinical benefit of bevacizumab + de Gramont schedule in heavily pretreated colorectal cancer patients. Cancer 2009. © 2009 American Cancer Society.